Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.68 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.63 |
| ▸ | CASP1 | P29466 | 5/20 | 0.63 |
| ▸ | CASP7 | P55210 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | ALPL | P05186 | 1/20 | 0.59 |
| ▸ | RORC | P51449 | 2/20 | 0.57 |
| ▸ | KLK7 | P49862 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11651866 | 0.94 | CDK5 (0.59) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL18048830 | 0.84 | CDK5 (0.68) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL9450612 | 0.84 | CDK5 (0.72) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL4024272 | 0.84 | CDK5 (0.68) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL29437355 | 0.84 | CDK5 (0.68) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL9450624 | 0.83 | KDM4E (0.73) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL1097083 | 0.83 | CDK5 (0.66) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL15798277 | 0.81 | CDK5 (1.00) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL6069376 | 0.80 | KDM4E (0.45) | CDK5CDK5R1KDM4EALDH1A1HPGD | |
| SCHEMBL13940909 | 0.80 | RORC (0.86) | CDK5CDK5R1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153410-B2 | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules | FOX CHASE CANCER CENTER (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153410-B2 | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules | FOX CHASE CANCER CENTER (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090048324-A1 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES | FOX CHASE CANCER CENTER (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048324-A1 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES | FOX CHASE CANCER CENTER (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048324-A1 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES | BMP2, BMP1, MYOF | CDK5 930/4885CDK5R1 1388/4885KDM4E 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.